These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 71542)

  • 21. Subcutaneous desferrioxamine: the effect of three years' treatment on liver, iron, serum ferritin, and comments on echocardiography.
    Flynn DM; Hoffbrand AV; Politis D
    Birth Defects Orig Artic Ser; 1982; 18(7):347-53. PubMed ID: 6819017
    [No Abstract]   [Full Text] [Related]  

  • 22. Evaluation of desferrioxamine and ascorbic acid for the treatment of chronic iron overload.
    Nienhuis AW; Delea C; Aamodt R; Bartter F; Anderson WF
    Birth Defects Orig Artic Ser; 1976; 12(8):177-85. PubMed ID: 795481
    [No Abstract]   [Full Text] [Related]  

  • 23. [Effect of continuous subcutaneous infusion of deferoxamine in a boy with congenital hypoplastic anemia].
    Ishitoya N; Gomibuchi I; Fujisawa K; Akatsuka J
    Rinsho Ketsueki; 1988 Sep; 29(9):1408-12. PubMed ID: 3216512
    [No Abstract]   [Full Text] [Related]  

  • 24. Blocking action of parenteral desferrioxamine on iron absorption in rodents and men.
    Levine DS; Huebers HA; Rubin CE; Finch CA
    Gastroenterology; 1988 Nov; 95(5):1242-8. PubMed ID: 3169492
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Iron chelation therapy with deferoxamine in Cooley anemia.
    Cohen A; Schwartz E
    J Pediatr; 1978 Apr; 92(4):643-7. PubMed ID: 633031
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical management of thalassemia. Decreasing iron stores during intensive chelation therapy.
    Cohen A; Schwartz E
    Ann N Y Acad Sci; 1980; 344():405-8. PubMed ID: 6930880
    [No Abstract]   [Full Text] [Related]  

  • 27. Intensive iron chelation therapy in beta-thalassemia major: some effects on iron metabolism and blood transfusion dependence.
    Silvestroni E; Bianco I; Graziani B; Lerone M; Valente M; Congedo P; Ponzini D; Costantini S
    Acta Haematol; 1982; 68(2):115-23. PubMed ID: 6812366
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Evaluation of iron balance in homozygous beta-thalassemia subjects treated with desferrioxamine administered subcutaneously].
    Ferrara M; Galdo Capotorti M; Ponte G; Esposito L
    Pediatria (Napoli); 1983; 91(4):371-7. PubMed ID: 6545400
    [No Abstract]   [Full Text] [Related]  

  • 29. High-dose intravenous chelation therapy with deferoxamine.
    Cohen A; Mizanin J; Schwartz E
    Prog Clin Biol Res; 1989; 309():125-31. PubMed ID: 2780746
    [No Abstract]   [Full Text] [Related]  

  • 30. Measurement of iron status.
    Pippard MJ
    Prog Clin Biol Res; 1989; 309():85-92. PubMed ID: 2675108
    [No Abstract]   [Full Text] [Related]  

  • 31. Iron absorption in iron-loading anaemias.
    Batey R
    Lancet; 1977 Oct; 2(8044):930. PubMed ID: 72269
    [No Abstract]   [Full Text] [Related]  

  • 32. The management of iron chelation therapy.
    Pippard MJ; Callender ST
    Br J Haematol; 1983 Aug; 54(4):503-7. PubMed ID: 6871105
    [No Abstract]   [Full Text] [Related]  

  • 33. Iron loading in congenital dyserythropoietic anaemias and congenital sideroblastic anaemias.
    Cazzola M; Barosi G; Bergamaschi G; Dezza L; Palestra P; Polino G; Ramella S; Spriano P; Ascari E
    Br J Haematol; 1983 Aug; 54(4):649-54. PubMed ID: 6871111
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vitamin C and iron.
    Nienhuis AW
    N Engl J Med; 1981 Jan; 304(3):170-1. PubMed ID: 7442737
    [No Abstract]   [Full Text] [Related]  

  • 35. Iron metabolism in thalassemia intermedia.
    Fiorelli G; Fargion S; Piperno A; Battafarano N; Cappellini MD
    Haematologica; 1990; 75 Suppl 5():89-95. PubMed ID: 2086386
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Survival and morbidity in transfusion-dependent thalassemic patients on subcutaneous desferrioxamine chelation. Nearly two decades of experience.
    Calleja EM; Shen JY; Lesser M; Grady RW; New MI; Giardina PJ
    Ann N Y Acad Sci; 1998 Jun; 850():469-70. PubMed ID: 9668587
    [No Abstract]   [Full Text] [Related]  

  • 37. Delayed decrease in serum ferritin in polytransfused children with thalassemia major after continuous subcutaneous infusions of desferrioxamine.
    Schettini F; Mautone A; Cavallo L; Altomare M; Montagna O; Dell'Edera L
    Acta Haematol; 1981; 66(2):96-101. PubMed ID: 6794319
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term desferrioxamine therapy in thalassemia.
    Modell CB; Beck J
    Ann N Y Acad Sci; 1974; 232(0):201-10. PubMed ID: 4528634
    [No Abstract]   [Full Text] [Related]  

  • 39. Chelation therapy in beta-thalassemia major. I. Intravenous and subcutaneous deferoxamine.
    Graziano JH; Markenson A; Miller DR; Chang H; Bestak M; Meyers P; Pisciotto P; Rifkind A
    J Pediatr; 1978 Apr; 92(4):648-52. PubMed ID: 633032
    [No Abstract]   [Full Text] [Related]  

  • 40. Iron metabolism and iron chelation in the thalassaemia disorders.
    Pippard MJ
    Haematologica; 1990; 75 Suppl 5():66-71. PubMed ID: 2086383
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.